Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Atopic Dermatitis Topic Center

Featured Article

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Maria Asimopoulos
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
Correlation Between Atopic Dermatitis, Neuropsychiatric Comorbidities in Pediatric Populations
08/26/2022
Edan Stanley
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
Acupuncture Might Reduce Itching in Patients With Atopic Dermatitis
07/29/2022
Maria Asimopoulos
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
JAK1 Inhibitor Improves Atopic Dermatitis Symptoms, Even in Nonresponders
07/22/2022
Jolynn Tumolo
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care

Newsfeed

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
Correlation Between Atopic Dermatitis, Neuropsychiatric Comorbidities in Pediatric Populations
08/26/2022
Edan Stanley
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
Acupuncture Might Reduce Itching in Patients With Atopic Dermatitis
07/29/2022
Maria Asimopoulos
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
JAK1 Inhibitor Improves Atopic Dermatitis Symptoms, Even in Nonresponders
07/22/2022
Jolynn Tumolo
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care
News
AI Tool for Drug Repurposing May Offer New Hope for Treating Rare and Neglected Diseases
09/27/2024
Harvard Medical School researchers unveil a potentially groundbreaking AI tool, TxGNN, that identifies potential drug candidates for 17 080 diseases, offering hope for patients with rare and neglected conditions.
Harvard Medical School researchers unveil a potentially groundbreaking AI tool, TxGNN, that identifies potential drug candidates for 17 080 diseases, offering hope for patients with rare and neglected conditions.
Harvard Medical School...
09/27/2024
First Report Managed Care
News
Impact of Multi-Drug Resistant Bacterial Infections on Patients With Bronchiectasis
09/27/2024
A study published in the Annals of Clinical Microbiology and Antimicrobials explores the impact of multidrug-resistant (MDR) bacterial infections on the clinical outcomes of adult patients with bronchiectasis, finding a significant increase...
A study published in the Annals of Clinical Microbiology and Antimicrobials explores the impact of multidrug-resistant (MDR) bacterial infections on the clinical outcomes of adult patients with bronchiectasis, finding a significant increase...
A study published in the Annals...
09/27/2024
First Report Managed Care
News
Understanding the Pharmacology and Clinical Application of siRNA Therapies
09/25/2024
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based therapies, relevant pharmacology insights, and care strategies aimed to enhance patient outcomes.
Explore the state of siRNA-based...
09/25/2024
First Report Managed Care
News
Impact of Long-Term Acute Care Hospital Closures on Patient Care Patterns and Outcomes
09/23/2024
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive...
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive...
A study published in JAMA...
09/23/2024
First Report Managed Care
News
Treatment Combination Advances Metastatic Urothelial Cancer Care
09/23/2024
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology...
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology...
Recent data has established...
09/23/2024
First Report Managed Care
News
Investigational 4F-PCC Non-Inferior to Control for Vitamin K Antagonist Reversal
09/23/2024
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study...
An investigational 4-factor...
09/23/2024
First Report Managed Care
News
Exploring the Mechanisms of FDA-Approved siRNA Treatments in Disease Therapy
09/20/2024
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking...
09/20/2024
First Report Managed Care
News
High Mortality and Impairment Rates Among Older Adults in Long-Term Acute Care Hospitals
09/20/2024
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals...
09/20/2024
First Report Managed Care
News
Addressing Stigma is Essential for Increasing PrEP Uptake and Adherence in HIV Prevention Efforts
09/20/2024
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated...
09/20/2024
First Report Managed Care
News
UC Davis Health Unveils Innovative Strategy to Shield Patients With COPD and Asthma From Wildfire Hazards
09/20/2024
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual...
09/20/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Recent Content

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Maria Asimopoulos
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement